Shares of Imperva, Inc. (NASDAQ:IMPV) have earned a consensus recommendation of “Hold” from the twenty-one research firms that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, seven have given a hold recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $51.86.

Several analysts recently issued reports on the company. Piper Jaffray Companies reissued a “neutral” rating and issued a $58.00 target price on shares of Imperva in a research note on Friday, October 13th. J P Morgan Chase & Co cut Imperva from a “neutral” rating to an “underweight” rating and set a $45.00 target price on the stock. in a research note on Tuesday. BidaskClub raised Imperva from a “sell” rating to a “hold” rating in a research note on Tuesday, September 12th. KeyCorp reissued a “hold” rating on shares of Imperva in a research note on Tuesday, October 24th. Finally, Evercore ISI reissued a “buy” rating and issued a $56.00 target price on shares of Imperva in a research note on Wednesday, November 8th.

Imperva (NASDAQ IMPV) traded down $0.35 during midday trading on Thursday, hitting $40.45. The company had a trading volume of 372,293 shares, compared to its average volume of 430,390. Imperva has a 12 month low of $37.05 and a 12 month high of $52.40.

Imperva (NASDAQ:IMPV) last posted its earnings results on Wednesday, November 8th. The software maker reported $0.33 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.22 by $0.11. The company had revenue of $83.89 million for the quarter, compared to analysts’ expectations of $83.79 million. Imperva had a negative return on equity of 8.52% and a net margin of 3.04%. Imperva’s quarterly revenue was up 22.6% on a year-over-year basis. During the same period last year, the firm earned $0.08 earnings per share. analysts predict that Imperva will post -0.52 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of IMPV. SG Americas Securities LLC bought a new stake in Imperva during the 3rd quarter valued at approximately $134,000. First Quadrant L P CA bought a new stake in Imperva during the 3rd quarter valued at approximately $136,000. Ameritas Investment Partners Inc. boosted its position in Imperva by 18.7% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,940 shares of the software maker’s stock valued at $141,000 after acquiring an additional 464 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its position in Imperva by 26.2% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,177 shares of the software maker’s stock valued at $201,000 after acquiring an additional 866 shares in the last quarter. Finally, Amalgamated Bank bought a new stake in Imperva during the 2nd quarter valued at approximately $206,000. 96.95% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This article was posted by American Banking News and is owned by of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/12/14/imperva-inc-impv-given-average-recommendation-of-hold-by-analysts.html.

About Imperva

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.

Analyst Recommendations for Imperva (NASDAQ:IMPV)

Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.